Engineered drug-protein nanoparticle complexes for folate receptor targeting

Biochemical Engineering Journal

Volumn 89, Issue , 2014, Pages 33-41

  Ren, Dongmei ^a   Kratz, Felix ^b   Wang, Szu Wen ^a  

^a University of California at Irvine   (United States)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Biomedical; Biomimetics; Bionanotechnology; Biosynthesis; Folic acid; Protein; Targeted drug delivery

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; BIOMIMETICS; BIOSYNTHESIS; DRUG DELIVERY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; PROTEINS; TUMORS;

BIOMEDICAL; BIONANOTECHNOLOGY; FOLIC ACIDS; FUNCTIONAL NANO MATERIALS; POLYETHYLENE GLYCOL (PEG); PROTEIN NANOPARTICLES; TARGETED DRUG DELIVERY; THERAPEUTIC APPLICATION;

SCAFFOLDS (BIOLOGY);

CYSTEINE; DOXORUBICIN; FOLATE RECEPTOR; MACROGOL; MALEIMIDE; NANOPARTICLE; PYRUVATE DEHYDROGENASE; RECOMBINANT PROTEIN;

ARTICLE; BIOMIMETICS; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; FLUORESCENCE IMAGING; NANOBIOTECHNOLOGY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN TARGETING;

ALEXA;

EID: 84903751301     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2013.09.008     Document Type: Article

References (37)

1. Uchida M., Klem M.T., Allen M., Suci P., Flenniken M., Gillitzer E., Varpness Z., Liepold L.O., Young M., Douglas T. Biological containers: protein cages as multifunctional nanoplatforms. Advanced Materials 2007, 19:1025-1042.
2. DiMarco R.L., Heilshorn S.C. Multifunctional materials through modular protein engineering. Advanced Materials 2012, 24:3923-3940.
3. Dalmau M., Lim S., Chen H.C., Ruiz C., Wang S.-W. Thermostability and molecular encapsulation within an engineered caged protein scaffold. Biotechnology and Bioengineering 2008, 101:654-664.
4. Allen M.D., Perham R.N. The catalytic domain of dihydrolipoyl acetyltransferase from the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus: expression, purification and reversible denaturation. FEBS Letters 1997, 413:339-343.
5. Ren D., Kratz F., Wang S.-W. Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 2011, 7:1051-1060.
6. Ren D., Dalmau M., Randall A., Shindel M.M., Baldi P., Wang S.-W. Biomimetic design of protein nanomaterials for hydrophobic molecular transport. Advanced Functional Materials 2012, 22:3170-3180.
7. Dalmau M., Lim S., Wang S.-W. Design of a pH-dependent molecular switch in a caged protein platform. Nano Letters 2008, 9:160-166.
8. Molino N.M., Bilotkach K., Fraser D.A., Ren D., Wang S.-W. Complement activation and cell uptake responses toward polymer-functionalized protein nanocapsules. Biomacromolecules 2012, 13:974-981.
9. Jiang W., Kim B.Y.S., Rutka J.T., Chan W.C.W. Nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnology 2008, 3:145-150.
10. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Letters 2006, 6:662-668.
11. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. Journal of Drug Targeting 2007, 15:457-464.
12. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery 2010, 9:615-627.
13. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. The Journal of Cell Biology 2009, 188:759-768.
14. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
15. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle-biomolecule interface for targeting and therapeutic delivery. Journal of Controlled Release 2012, 161:164-174.
16. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Advanced Drug Delivery Reviews 2000, 41:147-162.
17. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Advanced Drug Delivery Reviews 2012, 64(Supplement):342-352.
18. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Current Opinion in Chemical Biology 2009, 13:256-262.
19. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Analytical Biochemistry 2005, 338:284-293.
20. Abu Ajaj K., El-Abadla N., Welker P., Azab S., Zeisig R., Fichtner I., Kratz F. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative. European Journal of Cancer 2011, 48:2054-2065.
21. Hilgenbrink A.R., Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. Journal of Pharmaceutical Sciences 2005, 94:2135-2146.
22. Bharali D.J., Lucey D.W., Jayakumar H., Pudavar H.E., Prasad P.N. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. Journal of the American Chemical Society 2005, 127:11364-11371.
23. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine: The Official Journal of the American Academy of Nanomedicine 2011, 6:715-728.
24. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., Lazar P., Drückes P., Esser N., Drevs J., Rognan D., Bissantz C., Hinderling C., Folkers G., Fichtner I., Unger C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. Journal of Medicinal Chemistry 2002, 45:5523-5533.
25. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. Journal of Pharmaceutical Sciences 2000, 89:1452-1464.
26. Paulos C.M., Reddy J.A., Leamon C.P., Turk M.J., Low P.S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Molecular Pharmacology 2004, 66:1406-1414.
27. Wang S.-W., Monagle J., McNulty C., Putnam D., Chen H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. Journal of Pharmaceutical Sciences 2004, 93:2755-2767.
28. Destito G., Yeh R., Rae C.S., Finn M.G., Manchester M. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chemistry & Biology 2007, 14:1152-1162.
29. Folate as a targeting device for proteins utilizing folate receptor-mediated endocytosis. Drug Targeting 2000, 69-76. Humana Press. C. Delgado, R. Lee, P. Low (Eds.).
30. Zheng C.Y., Ma G., Su Z., Native P.A.G.E. eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in characterization of protein PEGylation. Electrophoresis 2007, 28:2801-2807.
31. Xu S., Olenyuk B.Z., Okamoto C.T., Hamm-Alvarez S.F. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Advanced Drug Delivery Reviews 2013, 65:121-138.
32. Ren Y., Wong S.M., Lim L.-Y. Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjugate Chemistry 2007, 18:836-843.
33. Wang Y., Yu L., Han L., Sha X., Fang X. Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines. International Journal of Pharmaceutics 2007, 337:63-73.
34. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. Journal of Controlled Release 2004, 100:247-256.
35. Scomparin A., Salmaso S., Bersani S., Satchi-Fainaro R., Caliceti P. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery. European Journal of Pharmaceutical Science 2011, 42:547-558.
36. Speelmans G., Staffhorst R.W.H.M., de Kruijff B., de Wolf F.A. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflet of the plasma membrane. Biochemistry 1994, 33:13761-13768.
37. Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opinion on Investigational Drugs 2007, 16:855-866.